For the Inventor, By the Inventor

Enter assignee name

Yangtze River Pharmaceutical Group Co., Ltd.

USPTO Granted Patents = 26

CIPO Patents = 4

EPO Patents = 11

Trademarks = 4

Forward Citations = 11

Loading Chart...

Loading Chart...

83 inventors (with patents filed for the assignee):

Jiong Lan (12 out of 34 patents)

Fusheng Zhou (10 out of 12 patents)

Haiying He (5 out of 54 patents)

4. Yuan Chen (5 out of 51 patents)

5. Songliang Wu (5 out of 8 patents)

6. Yuhe Wang (5 out of 5 patents)

7. Yunzhou Jin (5 out of 5 patents)

8. Zheng Wang (5 out of 43 patents)

9. Jing Xie (4 out of 23 patents)

10. Weidong Li (4 out of 16 patents)

11. Jinzhu Zhao (4 out of 5 patents)

12. Zhi Luo (4 out of 17 patents)

13. Dakun Qin (4 out of 5 patents)

14. Qiang Lv (4 out of 4 patents)

15. Xiangyu He (4 out of 5 patents)

26 patents: Sort by Forward Citations

1. 11174254 - Aniline-substituted 1,2-dihydropyrrol[3,4-C]pyridin/pyrimidin-3-one derivative and use thereof (2021-11-16),

2. 11168088 - Pyridylamino substituted heterotricyclic compounds, and preparation method and pharmaceutical use thereof (2021-11-09),

3. 11155546 - 4,6,7-trisubstituted 1,2-dihydropyrrolo[3,4-c]pyridin/pyrimidin-3-one derivatives and uses thereof (2021-10-26),

4. 11104664 - 4,5,6-trisubstituted indazole derivatives, and preparation method and pharmaceutical use thereof (2021-08-31),

5. 10947202 - Sodium ion channel inhibitors and pharmaceutically acceptable salts and polymorphs thereof and uses thereof (2021-03-16),

6. 10947185 - Crystal form of dezocine and preparation method therefor (2021-03-16),

7. 10912775 - Crystal form of orexin receptor antagonist compound, and preparation method and application thereof (2021-02-09),

8. 10898486 - Crystal form of orexin receptor antagonist compound, and preparation method and application thereof (2021-01-26),

9. 10874674 - Crystal form of orexin receptor antagonist compound, and preparation method and application thereof (2020-12-29),

10. 10815197 - N-sulfonyl benzamides as voltage-gated sodium channel inhibitors (2020-10-27),

11. 10793549 - Sulfuryl-substituted benzoheterocyclic derivative, preparation method and medical use thereof (2020-10-06),

12. 10668066 - Crystal form of orexin receptor antagonist compound, and preparation method and application thereof (2020-06-02),

13. 10577346 - Benzobicycloalkane derivatives, their preparation and pharmaceutical use thereof (2020-03-03),

14. 10561646 - EGFR inhibitor and pharmaceutically acceptable salt and polymorph thereof, and use thereof (2020-02-18),

15. 10544137 - PI3K inhibitor, and pharmaceutically acceptable salt, polycrystalline form, and application thereof (2020-01-28),

Yangtze River Pharmaceutical Group Co., Ltd. is a leading pharmaceutical company based in China. They specialize in the research, development, manufacturing, and distribution of a wide range of pharmaceutical products. With a strong focus on innovation, quality, and customer satisfaction, Yangtze River Pharmaceutical Group has become a trusted name in the global pharmaceutical industry. For more information, please visit their official website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

26 Patents

#24 in Jiangsu

#1,047 in China

#24,104 in the World

Yangtze River Pharmaceutical Group Co., Ltd.

Forward Citations = 11

83 inventors:

Jiong Lan (12 out of 34 patents)

Fusheng Zhou (10 out of 12 patents)

Haiying He (5 out of 54 patents)

4. Yuan Chen (5 out of 51 patents)

5. Songliang Wu (5 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…